Sign In
Buy CVM
$1.22
-0.160 (-11.59%)
At Close: Jul 13, 2026
CEL-SCI’s Pivotal Phase 3 Study has reached the required number of events to evaluate data for Multikine in treatment of Head and Neck Cancer.
CEL-SCI’s Pivotal Phase 3 Study has reached the required number of events to evaluate data for Multikine in treatment of Head and Neck Cancer.
Some countries are squashing the coronavirus curve. Vietnam is one
06:42am, Tuesday, 28'th Apr 2020
The developing country of more than 95 million people has less than 300 cases and no deaths
81 Biggest Movers From Friday
09:33am, Monday, 27'th Apr 2020
Gainers
Mesoblast Limited (NASDAQ: MESO) shares climbed 139.5% to close at $15.45 on Friday after the company reported 10 out of 12 patients with ventilator-dependent...
Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment
11:48am, Friday, 24'th Apr 2020
Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
01:15pm, Thursday, 23'rd Apr 2020
CEL-SCI reports recent data review by the Independent Data Monitoring Committee for its pivotal Phase 3 head and neck cancer study.
Which Stocks Will Be The Big COVID-19 Winners?
11:50am, Thursday, 16'th Apr 2020
It’s natural during a crisis… Investors want to find the companies that will help solve the problem and come out as big winners. The company or companies that do produce effective treatments and v
Brazil’s New Blockchain Data Tool Cost $250K, Runs on Quorum
06:00pm, Friday, 10'th Apr 2020
Brazil's central bank spent 1.3 million Brazilian reals (USD $250K) over two years building its new database for financial regulators on Quorum, replacing a slow and expensive paper-based system with
Important Update For CEL-SCI Corporation Annual Meeting of Shareholders
12:00pm, Wednesday, 08'th Apr 2020
Important update for CEL-SCI Corporation Annual Meeting of Shareholders.
CEL-SCI Announces Change of Location to 2020 Annual Meeting of Shareholders
08:05pm, Monday, 30'th Mar 2020
CEL-SCI announces change of location to 2020 Annual Meeting of Shareholders.
Pharma, Biotech Players Step Up Efforts Against Coronavirus
12:50pm, Friday, 27'th Mar 2020
Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.
CEL-SCI Announces the Closing of Its $7.7 Million Bought Deal
03:05pm, Thursday, 26'th Mar 2020
CEL-SCI announces the closing of its $7.7 million bought deal.
